A detailed history of Blue Fin Capital, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Blue Fin Capital, Inc. holds 4,711 shares of AMGN stock, worth $1.39 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
4,711
Previous 4,824 2.34%
Holding current value
$1.39 Million
Previous $1.51 Million 0.66%
% of portfolio
0.29%
Previous 0.3%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$309.38 - $337.38 $34,959 - $38,123
-113 Reduced 2.34%
4,711 $1.52 Million
Q2 2024

Jul 30, 2024

BUY
$262.75 - $319.31 $14,714 - $17,881
56 Added 1.17%
4,824 $1.51 Million
Q1 2024

May 14, 2024

SELL
$268.87 - $324.56 $47,589 - $57,447
-177 Reduced 3.58%
4,768 $1.36 Million
Q4 2023

Feb 06, 2024

SELL
$255.7 - $288.46 $26,848 - $30,288
-105 Reduced 2.08%
4,945 $1.42 Million
Q3 2023

Oct 19, 2023

SELL
$218.65 - $271.46 $27,549 - $34,203
-126 Reduced 2.43%
5,050 $1.36 Million
Q2 2023

Jul 31, 2023

SELL
$214.27 - $253.37 $16,713 - $19,762
-78 Reduced 1.48%
5,176 $1.15 Million
Q1 2023

May 12, 2023

SELL
$225.79 - $275.2 $77,445 - $94,393
-343 Reduced 6.13%
5,254 $1.27 Million
Q4 2022

Jan 23, 2023

SELL
$229.03 - $291.01 $71,915 - $91,377
-314 Reduced 5.31%
5,597 $0
Q3 2022

Nov 04, 2022

BUY
$224.46 - $253.15 $96,068 - $108,348
428 Added 7.81%
5,911 $1.33 Million
Q2 2022

Aug 08, 2022

SELL
$230.71 - $256.74 $13,842 - $15,404
-60 Reduced 1.08%
5,483 $1.33 Million
Q1 2022

Apr 12, 2022

BUY
$219.27 - $242.57 $7,893 - $8,732
36 Added 0.65%
5,543 $1.34 Million
Q4 2021

Jan 19, 2022

BUY
$198.88 - $227.6 $5,767 - $6,600
29 Added 0.53%
5,507 $1.24 Million
Q3 2021

Oct 25, 2021

SELL
$212.27 - $248.7 $18,255 - $21,388
-86 Reduced 1.55%
5,478 $1.16 Million
Q2 2021

Jul 19, 2021

SELL
$233.58 - $259.14 $51,387 - $57,010
-220 Reduced 3.8%
5,564 $1.36 Million
Q1 2021

May 05, 2021

SELL
$221.91 - $258.6 $82,994 - $96,716
-374 Reduced 6.07%
5,784 $1.44 Million
Q4 2020

Jan 28, 2021

SELL
$216.38 - $257.67 $8,222 - $9,791
-38 Reduced 0.61%
6,158 $1.42 Million
Q3 2020

Oct 28, 2020

BUY
$234.65 - $260.95 $15,721 - $17,483
67 Added 1.09%
6,196 $1.57 Million
Q2 2020

Aug 10, 2020

SELL
$197.81 - $242.74 $107,410 - $131,807
-543 Reduced 8.14%
6,129 $1.45 Million
Q1 2020

Apr 28, 2020

SELL
$182.24 - $241.7 $46,471 - $61,633
-255 Reduced 3.68%
6,672 $1.35 Million
Q4 2019

Feb 10, 2020

SELL
$189.21 - $243.2 $23,840 - $30,643
-126 Reduced 1.79%
6,927 $1.67 Million
Q3 2019

Nov 07, 2019

SELL
$174.11 - $208.62 $97,327 - $116,618
-559 Reduced 7.34%
7,053 $1.36 Million
Q2 2019

Jul 22, 2019

BUY
$166.7 - $195.41 $6,001 - $7,034
36 Added 0.48%
7,612 $1.4 Million
Q1 2019

Apr 23, 2019

BUY
$180.87 - $203.88 $8,320 - $9,378
46 Added 0.61%
7,576 $1.44 Million
Q4 2018

Jan 16, 2019

BUY
$178.4 - $208.25 $14,450 - $16,868
81 Added 1.09%
7,530 $1.47 Million
Q3 2018

Nov 09, 2018

BUY
$185.29 - $208.89 $125,441 - $141,418
677 Added 10.0%
7,449 $1.54 Million
Q2 2018

Aug 06, 2018

BUY
$166.05 - $186.51 $15,940 - $17,904
96 Added 1.44%
6,772 $1.25 Million
Q4 2017

Jan 26, 2018

BUY
$168.79 - $188.59 $62,452 - $69,778
370 Added 5.87%
6,676 $1.16 Million
Q3 2017

Oct 11, 2017

BUY
$167.29 - $191.0 $1.05 Million - $1.2 Million
6,306
6,306 $1.18 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $157B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Blue Fin Capital, Inc. Portfolio

Follow Blue Fin Capital, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Fin Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Blue Fin Capital, Inc. with notifications on news.